[73] demonstrated compelling clinical utility, reporting significant therapeutic benefit from TRK inhibitors in an infantile fibrosarcoma harboring TPM3‐NTRK1, even in the complex setting of Bloom syndrome, underscoring its potency as a target. Here, TPM3 is linked to fibrosarcoma.